论文部分内容阅读
血管紧张素转换酶抑制剂具有药理性预适应作用 ,能够减轻缺血再灌注后心肌心律失常的发生。血管紧张素转换酶抑制剂预适应抗心律失常的机制从电生理学上认为血管紧张素转换酶抑制剂通过改变缺血期和再灌注期心肌细胞的电活动 ,影响心肌细胞电稳定性 ;从内源性机制上认为血管紧张素转换酶抑制剂通过减少血管紧张素Ⅱ的生成 ,减慢缓激肽的降解增加缓激肽的积聚 ,进而通过BK B2受体途径激活内源性保护机制 ,发挥抗心律失常作用。
Angiotensin-converting enzyme inhibitors have the pharmacological preconditioning, can reduce the occurrence of myocardial arrhythmia after ischemia-reperfusion. Angiotensin-converting enzyme inhibitors preconjugated anti-arrhythmia mechanism from the electrophysiological view that angiotensin-converting enzyme inhibitors by changing the ischemic and reperfusion myocardial electrical activity, affecting myocardial electrical stability; from within Originally mechanism that angiotensin-converting enzyme inhibitors by reducing angiotensin II production, slowing down the degradation of bradykinin increased bradykinin accumulation, and then through the BK B2 receptor pathway to activate endogenous protective mechanisms, play Anti-arrhythmic effect.